Thus, theoretically, the high specificity and efficacy of CRISPR-Cas9 in blocking MMP-9 expression associated with tumor-specific transfection vectors may minimize the high volume of side effects observed with systemic MMP inhibitors. The gene discussed is MMP9; the disease is neoplasm.